Evaluation of hbeta;D-1 and hbeta; D-2 levels in saliva of patients with oral mucosal diseases / Evaluación de los niveles de hbeta; D-1 y hbeta;D-2 en la Saliva de pacientes con enfermedades de la mucosa oral

OBJECTIVE: This study aimed to determine a possible correlation between oral mucosal disease and salivary concentrations of the antimicrobial peptides human beta-defensin-1 (hβD-1) and human betadefensin- 2 (hβD-2). METHOD: The present work focussed on the establishment of a reversed phase-high performance liquid chromatography (RP-HPLC) procedure to quantify human beta-defensins (hβD-1 and hβD-2) in saliva samples of patients with oral diseases such as lichen planus (n = 10), Behçet (n = 10) and recurrent apthous stomatitis (n = 10). RESULTS: Linear calibration range for hβD-1 and hβD-2 defensins was 1.67−200 µg mL-1 and 3.13− 100 µg mL-1 with R2 values of 0.9998 and 0.996, correspondingly. The concentration of beta-defensins in saliva was determined by comparing the peak areas of eluted hβD-1 and hβD-2 with that of their standards. The variation of the amount of beta-defensins was evaluated by comparisons of the results obtained from the patients with oral mucosal diseases before and after treatments and the control subjects. The limit of detection (LOD) and limit of quantification (LOQ) were found to be 1.62 µg mL- 1 and 5.39 µg mL-1 for hβD-1 and 0.94 µg mL-1 and 3.13 µg mL-1 for hβD-2, respectively. CONCLUSION: The salivary beta-defensin concentration was significantly higher in patients with oral mucosal diseases than in healthy volunteers; furthermore, in patients with oral mucosal diseases, the concentration was significantly higher before treatment than after treatment.

OBJETIVO: Este estudio tuvo por objeto determinar una posible correlación entre la enfermedad de la mucosa oral y las concentraciones salivales de la beta-defensina humana 1 (hβD-1) y la beta-defensina humana 2 (hβD-2) de los péptidos antimicrobianos. MÉTODO: El presente trabajo estuvo encaminado al establecimiento de un procedimiento de cromatografía líquida de alta eficacia de fase reversa (RP-HPLC) para cuantificar las beta-defensinas humanas (hβD-1 y hβD-2) en muestras de saliva de pacientes con enfermedades orales como el liquen plano (n = 10), Behçet (n = 10), y la estomatitis aftosa recurrente (n = 10). RESULTADOS: El rango de calibración lineal de las defensinas hβD-1 y hβD-2 fue 1.67-200 µg mL-1 y 3.13-100 µg mL-1 con valores R2 de 0.9998 y 996, respectivamente. La concentración de beta-defensinas en la saliva se determinó utilizando el área de sus estándares. La variación de la cantidad de beta defensinas fue evaluada por comparaciones de los resultados obtenidos de los pacientes con enfermedades de la mucosa oral, antes y después de los tratamientos y los sujetos de control. Se halló que el límite de detección (LDD) y el límite de cuantificación (LDC) fueron 1.62 µg mL-1 y 5.39 µg mL- 1 para hβD-1 y 0.94 µg mL-1 y 3.13 µg mL-1 hβD-2, respectivamente. CONCLUSIÓN: La concentración de beta-defensina salival fue significativamente mayor en los pacientes con enfermedades de la mucosa oral que en los voluntarios sanos. Además, en pacientes con enfermedades de la mucosa oral, la concentración fue significativamente mayor antes del tratamiento que después del tratamiento.

Evaluation of hbetaD-1 and hbetaD-2 levels in saliva of patients with oral mucosal diseases.

OBJECTIVE: This study aimed to determine a possible correlation between oral mucosal disease and salivary concentrations of the antimicrobial peptides human beta-defensin-1 (hbetaD-1) and human beta-defensin-2 (hbetaD-2). METHOD: The present work focussed on the establishment of a reversed phase-high performance liquid chromatography (RP-HPLC) procedure to quantify human beta-defensins (hbetaD-1 and hbetaD-2) in saliva samples of patients with oral diseases such as lichen planus (n = 10), Behçet (n = 10) and recurrent apthous stomatitis (n = 10). RESULTS: Linear calibration range for hbetaD-1 and hbetaD-2 defensins was 1.67-200 microg mL-1 and 3.13 -100 PG mL-1 with R2 values of 0.9998 and 0.996, correspondingly. The concentration of beta-defensins in saliva was determined by comparing the peak areas of eluted hbetaD-1 and hbetaD-2 with that of their standards. The variation of the amount of beta-defensins was evaluated by comparisons of the results obtained from the patients with oral mucosal diseases before and after treatments and the control subjects. The limit of detection (LOD) and limit of quantification (LOQ) were found to be 1.62 microg mL-Sand 5.39 microg mL-1 for hbetaD-1 and 0.94 mig mL-1 and 3.13 microg mL-1 for hbetalD-2, respectively. CONCLUSION: The salivary beta-defensin concentration was significantly higher in patients with oral mucosal diseases than in healthy volunteers; furthermore, in patients with oral mucosal diseases, the concentration was significantly higher before treatment than after treatment.

Reconstruction of an unusual orocutaneous fistula by using a bilobed flap.

Orocutaneous fistulas or cutaneous sinus tracts of dental origin are pathologic communications between the cutaneous surface of the face and the oral cavity. They are relatively uncommon and may be easily misdiagnosed. In this report, management of an orocutaneous fistula of dental origin, which endured for 20 years, by using an extraoral bilobed skin flap, an intraoral buccal rotational mucosal flap and allogenic bone graft, is presented.

Posterior segmental osteotomy of maxillary edentulous ridge: an alternative to vertical reduction.

The posterior segmental maxillary osteotomy (PSMO) can be used as an alternative procedure to vertical reduction of the edentulous posterior maxilla. Surgical intrusion of the segment resulted in an adequate interarch space for prosthetic restoration without cortical bone loss and widening of the edentulous ridge and the mobilized keratinized mucosa as would be the case if vertical alveolar reduction had been performed.

Does the timing and method of rapid maxillary expansion have an effect on the changes in nasal dimensions?

The aim of this study was to assess the effects of rapid maxillary expansion (RME) and surgical assisted rapid maxillary expansion (SARME) on nasopharyngeal area. The study group consisted of 30 subjects in the permanent dentition who had both maxillary constriction and a posterior cross-bite. The patients were divided into two groups, RME and SARME. The subjects in the RME group consisted of 15 patients (eight girls, seven boys) whose average age was 12.1 +/- 1.1 years. The SARME group also consisted of 15 patients (eight boys, seven girls) whose mean age was 18.4 +/- 1.4 years. An acrylic bonded RME appliance was used in both groups. Surgery was performed using lateral cortical osteotomies in the SARME group. The nasopharyngeal and respiratory area was determined using a digital planimeter on lateral cephalometric radiographs taken before and after RME. Nasal cavity width was evaluated on postero-anterior radiographs. Nasal dimension was measured using planimeter measurements of the respiratory and nasopharyngeal areas before and after treatment. The data obtained were analyzed using SPSS. Comparisons within the groups were carried out with paired t-tests and comparisons between the groups were with a Student's t-test. In both groups, the respiratory area and the ratio of the respiratory area to nasopharyngeal (RA/NA) area increased following RME. There were no statistically significant differences between the groups. Nasal cavity width and maxillary width also increased, but the difference between the groups was not significant. Following RME, various differences in both the maxilla and surrounding bones occurred and nasal width increased with a decrease in nasal airway resistance. At the end of treatment there were increases in the width of the nasal floor near the midpalatal suture and nasal cavity. As the maxillary structures separated, the outer walls of the nasal cavity moved laterally resulting in an increase in internasal volume. Nasal resistance decreased and respiratory area increased in patients treated with RME.